Mulberry Leaf

Mulberry leaf is a botanical ingredient derived from the leaves of Morus alba, the white mulberry tree. It has a long history of use in traditional Chinese and Korean herbal medicine, primarily in the context of metabolic wellness and carbohydrate management. In modern dietary supplements, it is most commonly standardised to 1-deoxynojirimycin (DNJ), a compound that has been studied for its effect on post-meal glucose response.

Brands use mulberry leaf in gummy formats because it is heat-stable, soluble, and has a mild taste that works well in fruit-flavoured gummies. Its low cost tier makes it accessible for mass-market positioning, and it pairs effectively with other metabolic-support ingredients like Chromium and Inositol. As a botanical on the EFSA on-hold list, it cannot carry authorised health claims under Reg. 432/2012, but it remains one of the most familiar and commercially understood botanical actives for glucose metabolism support across EU and US markets.

Origin and history

White mulberry (Morus alba) is native to China and has been cultivated for thousands of years, primarily for silkworm rearing. The leaves have been used in traditional Chinese medicine for metabolic and digestive wellness, and the practice of using mulberry leaf tea for post-meal glucose management is well documented in East Asian herbal traditions. The tree was introduced to Europe and the Americas during the silk trade and has since naturalised in many temperate regions.

Industrial production of mulberry leaf extract involves harvesting the leaves, drying them, and extracting the active compounds—primarily DNJ—using water or ethanol. The extract is then standardised to a consistent DNJ content, typically around 1%, and spray-dried into a powder suitable for gummy and sachet manufacturing. The supply chain is well established, with major production in China, Korea, and Japan, and the ingredient is widely available at commodity pricing.

Scientific overview

The primary active compound in mulberry leaf is 1-deoxynojirimycin (DNJ), a polyhydroxylated piperidine alkaloid that acts as a competitive inhibitor of alpha-glucosidase enzymes in the small intestine. By slowing the breakdown of complex carbohydrates into absorbable monosaccharides, DNJ reduces the rate of glucose absorption after a meal, leading to a blunted postprandial glucose spike. This mechanism is well characterised in the scientific literature and is the basis for most commercial positioning of mulberry leaf supplements.

Bioavailability of DNJ is relatively low due to its hydrophilic nature, but the compound acts locally in the gut lumen, so systemic absorption is not required for its primary effect. Standardised extracts with 1% DNJ are the most common form used in supplements, though whole leaf powder is also available at a lower cost per serving. The ingredient is heat-stable and soluble, making it well suited for gummy manufacturing without significant degradation during processing.

Manufacturing watchpoints include ensuring consistent DNJ standardisation across batches, as the active content can vary with harvest season and processing method. The cost-per-mg is low, making mulberry leaf one of the more economical botanical actives for gummy formulations. However, brands should note that the onset of effect typically takes 2–3 weeks of consistent use, which should be reflected in consumer communication and product positioning.

Mulberry leaf is one of the most familiar and commercially understood botanical actives for glucose metabolism support across EU and US markets. Its low cost tier and mild taste make it an attractive option for mass-market gummy ranges targeting metabolic wellness, sugar craving management, and post-meal glucose response. The ingredient pairs naturally with Chromium and Inositol, allowing brands to build comprehensive metabolic support formulations with multiple angles of claim coverage.

From a formulation and manufacturing perspective, mulberry leaf is heat-stable and soluble, which means it integrates cleanly into standard gummy production lines without requiring cold processing or encapsulation. The mild, slightly sweet taste is easy to mask with fruit flavours, and the ingredient does not cause the texture or stability issues that some other botanicals can introduce. The low cost tier also allows for flexible dosing within the 200–1500 mg range without significantly impacting per-unit cost.

For pack copy, brands should position mulberry leaf around general wellness and traditional use, or co-formulate with authorised nutrients for claim coverage. As a botanical on the EFSA on-hold list, no authorised health claims are available under Reg. 432/2012, so claim wording must come from co-formulated ingredients such as Chromium (contributes to normal macronutrient metabolism) or Inositol (contributes to normal insulin sensitivity). DAT reviews claim strategy, dosing, and formulation per project to ensure compliance with target market regulations.